(Total Views: 548)
Posted On: 05/21/2021 3:27:13 PM
Post# of 155732
Here are two news articles from India. There is no specific mention of Leronlimab, but the government intends to pay for Covid treatments for patients in private hospitals whose income is below poverty level, so this could prove beneficial. Haryana is a state in India and Chandigarh is the capital.
https://timesofindia.indiatimes.com/city/chan...831716.cms
CHANDIGARH: Haryana chief minister Manohar Lal Khattas on Friday announced that the state government will bear all expenses of Covid-19 patients belonging to below poverty line (BPL) category undergoing treatment in private hospitals.
Along with treatment of Covid patients, the CM said focus should also be put on making adequate arrangements to deal with the patients suffering from post-Covid complications, including keeping a close vigil on black fungus cases.
https://timesofindia.indiatimes.com/india/ind...827757.cms
New Delhi/New York: Pfizer and the government are at
loggerheads over a demand by the US drugmaker for legal protection from any claims linked to the use of its Covid-19 vaccine in one of the world's biggest markets, two sources told Reuters.
India has not given any manufacturer of a Covid-19 vaccine indemnity against the costs of compensation for any severe side effects, which is a condition Pfizer has obtained in many countries where its shots have already been widely rolled out, including Britain and the United States.
https://timesofindia.indiatimes.com/city/chan...831716.cms
CHANDIGARH: Haryana chief minister Manohar Lal Khattas on Friday announced that the state government will bear all expenses of Covid-19 patients belonging to below poverty line (BPL) category undergoing treatment in private hospitals.
Along with treatment of Covid patients, the CM said focus should also be put on making adequate arrangements to deal with the patients suffering from post-Covid complications, including keeping a close vigil on black fungus cases.
https://timesofindia.indiatimes.com/india/ind...827757.cms
New Delhi/New York: Pfizer and the government are at
loggerheads over a demand by the US drugmaker for legal protection from any claims linked to the use of its Covid-19 vaccine in one of the world's biggest markets, two sources told Reuters.
India has not given any manufacturer of a Covid-19 vaccine indemnity against the costs of compensation for any severe side effects, which is a condition Pfizer has obtained in many countries where its shots have already been widely rolled out, including Britain and the United States.
(4)
(0)
